WEBULL

ADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus

Simply Wall St · 2d ago

Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and revenue compared with last year.

See our latest analysis for ADMA Biologics.

At a share price of $8.87, ADMA Biologics has seen short term momentum soften, with the share price return down over the past week and quarter, while a very large 5 year total shareholder return shows how strong earlier gains have been. Recent price weakness, alongside anticipation around the upcoming earnings release, suggests investors are reassessing both growth potential and risk after a long period of strong total returns.

If this kind of reassessment has you looking beyond a single stock, it could be a good moment to scan for other ideas in healthcare related AI, starting with 40 healthcare AI stocks.

ADMA Biologics now appears to be a solid plasma-based business whose stock has stumbled, which puts the focus squarely on price. After such sharp long term gains, is the current valuation still reasonable?

Most Popular Narrative: 49.6% Undervalued

With ADMA Biologics last closing at $8.87 against a narrative fair value of $17.60, the current market price sits well below what this widely followed valuation framework implies.

Expansion of plasma collection volumes and the acquisition of new facilities are set to increase production capacity and supply chain resilience, positioning ADMA to capture greater market share and further accelerate revenue growth and earnings over the long term.

Read the complete narrative.

Want to see how this outlook turns into that fair value for ADMA Biologics? The narrative leans heavily on future revenue, margins and the earnings multiple that ties it all together.

Result: Fair Value of $17.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the ADMA Biologics story could shift quickly if the plasma yield process runs into setbacks or if ongoing class action lawsuits weigh further on sentiment.

Find out about the key risks to this ADMA Biologics narrative.

Next Steps

If sentiment around ADMA Biologics feels mixed, this is a good time to move quickly and check the underlying facts yourself. To see what investors are optimistic about, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond ADMA Biologics?

If you are weighing what comes next after ADMA Biologics, do not stop here. Fresh opportunities often appear where fewer investors are already looking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.